[HTML][HTML] KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation
M Maio, MS Carlino, AM Joshua, E McWhirter… - European Journal of …, 2022 - Elsevier
Objectives Parts 4 and 5 of the phase 1/2 KEYNOTE-022 study investigated the maximum
tolerated dose (MTD), safety, and efficacy of pembrolizumab plus trametinib in solid tumours …
tolerated dose (MTD), safety, and efficacy of pembrolizumab plus trametinib in solid tumours …
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation
M Maio, MS Carlino, AM Joshua… - … journal of cancer …, 2022 - pubmed.ncbi.nlm.nih.gov
Objectives Parts 4 and 5 of the phase 1/2 KEYNOTE-022 study investigated the maximum
tolerated dose (MTD), safety, and efficacy of pembrolizumab plus trametinib in solid tumours …
tolerated dose (MTD), safety, and efficacy of pembrolizumab plus trametinib in solid tumours …
Keynote-022: pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation
M Maio, MS Carlino, AM Joshua… - European …, 2022 - researchdirect.westernsydney.edu …
Objectives: Parts 4 and 5 of the phase 1/2 KEYNOTE-022 study investigated the maximum
tolerated dose (MTD), safety, and efficacy of pembrolizumab plus trametinib in solid tumours …
tolerated dose (MTD), safety, and efficacy of pembrolizumab plus trametinib in solid tumours …
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation
M Maio, MS Carlino, AM Joshua… - European Journal of …, 2022 - ejcancer.com
Objectives Parts 4 and 5 of the phase 1/2 KEYNOTE-022 study investigated the maximum
tolerated dose (MTD), safety, and efficacy of pembrolizumab plus trametinib in solid tumours …
tolerated dose (MTD), safety, and efficacy of pembrolizumab plus trametinib in solid tumours …
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation
M Maio, MSS Carlino, AM Joshua, E McWhirter… - 2022 - wslhd.intersearch.com.au
OBJECTIVES: Parts 4 and 5 of the phase 1/2 KEYNOTE-022 study investigated the
maximum tolerated dose (MTD), safety, and efficacy of pembrolizumab plus trametinib in …
maximum tolerated dose (MTD), safety, and efficacy of pembrolizumab plus trametinib in …
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation.
M Maio, MS Carlino, AM Joshua… - European Journal of …, 2021 - europepmc.org
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or
advanced solid tumours irrespective of BRAF mutation. - Abstract - Europe PMC Sign in …
advanced solid tumours irrespective of BRAF mutation. - Abstract - Europe PMC Sign in …